Urolithin B suppressed osteoclast activation and reduced bone loss of osteoporosis via inhibiting ERK / NF‐κB pathway

OBJECTIVES: The main target of current drugs for alleviating bone loss is osteoclasts. However, the long-term application of such drugs will also cause side effects. Therefore, it is of great need to develop new and safer therapeutics for osteoporosis. In recent years, drug development based on gut ... View More